Study Finds Concerning Trends Among E-cigarette Users in UK

Sep.30.2024
Study Finds Concerning Trends Among E-cigarette Users in UK
A study of 1,020 e-cigarette users found 39% may buy from unregulated sources, raising concerns about safety.

According to a report by Internewscast on September 29th, a study conducted on 1,020 e-cigarette users found that 39% of them admitted that they may purchase e-cigarettes from unregulated channels that have not been officially safety-checked.


The research results also show that one-third of the respondents believe that their nicotine consumption will increase. However, 22% of people believe that the upcoming law will motivate them to quit their e-cigarette habit.


A study commissioned by the nicotine pouch brand Übbs and retailer Haypp, carried out by OnePoll.com, aimed to respond to the UK government's commitment to achieve a "smoke-free Britain". Earlier this year, the UK government announced legislation that will restrict the sale and use of disposable e-cigarettes by 2025.


According to the survey, since the ban on e-cigarettes was announced, 24% of respondents have attempted to quit using them. 26% of respondents have switched to other alternatives, such as traditional cigarettes (36%), nicotine pouches (26%), and gum (25%).


The study also found that 85% of the respondents had smoked before switching to e-cigarettes, with 52% of them expressing concern about reverting to smoking habits after the ban is implemented.


The spokesperson for the Übbs brand, Steve McGeough, stated that,


Hearing e-cigarette users say they will seriously consider switching to smoking after the ban is implemented is really concerning. Additionally, research also shows that some people may even seek unregulated e-cigarettes, which is very worrying in terms of quality and safety. Our research suggests that while disposable e-cigarettes may be gradually phased out, there are still many safe and regulated alternatives available now or when the ban comes into effect. Nicotine pouches are a popular choice, providing support for the UK's goal to become a smoke-free nation.


The study also found that 73% of e-cigarette users have not tried any e-cigarette alternatives. However, among them, 28% are most likely to try traditional cigarettes, 21% are willing to try gum, and 25% are open to trying nicotine pouches.


Additionally, 30% of respondents are "very aware" of the risks of using unregulated e-cigarettes. The most familiar features of such devices among respondents include the lack of nicotine warning labels (41%) and the absence of emissions testing information (30%). When looking for alternatives, 52% of people prioritize the smell and taste of the product, followed by considerations of safety and quality assurance (50%), and the product's discreteness (33%). 30% of individuals prefer products that are "readily available," while 24% believe that open system e-cigarettes are too complicated.


The study also revealed that running out of battery is the most annoying thing when using e-cigarettes (32%), followed by not being able to use them freely anytime and anywhere (30%). Another major concern is having to leave social gatherings to smoke and missing out on time with friends (23%), and the issue of not being able to use e-cigarettes on airplanes (21%).


Haypp spokesperson Markus Lindbald stated,


From a positive perspective, it is a good phenomenon that before the ban is implemented, so many people are trying to quit e-cigarettes or explore other low-risk alternatives, such as nicotine pouches, instead of turning back to smoking. Based on the nearly smokeless experience in Sweden, nicotine pouches can play an important role in reducing smoking rates and improving public and personal health.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Juul Labs displayed its JUUL2 e-cigarette system alongside existing products, age-verification messaging and mobile coupons, 2Firsts observed. The JUUL2 device and Virginia Tobacco and Polar Menthol pods received FDA marketing authorization in August 2026. Booth materials highlighted longer battery life, greater e-liquid capacity and connected-device features. A TruAge sign and a mobile coupon presentation also featured at the booth, with weekly offers available to age-verified adult nicotine consumers at participating retailers.
EXPO
Oct.09